Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Obesity is a growing epidemic with multiple associated comorbidities including type 2 diabetes, hypertension and hyperlipidaemia. Multiple studies have shown that weight loss can improve these obesity RR factors. But weight loss is difficult. There is an urgent need for new and more efficacious pharmacological treatments to help curtail this growing epidemic. There have been previous studies looking at the use of phentermine and topiramate as single agents for weight loss. In the CONQUER trial, Gadde and colleagues have asked whether a combination of these two agents could provide a more effective treatment option for obesity with fewer side effects.
The CONQUER trial is a randomised controlled trial to assess the effects of two different doses of the combination of controlled-release (CR) phentermine plus topiramate versus placebo on weight loss. The multicentred study enrolled 2487 patients with a body mass index between 27 and 45 kg/m …
Competing interests LJA is a consultant, speaker and advisor and receives research support from Abbott, Amylin, Arena, BMIQ, GI Dynamics, GSK, Novo Nordisk, Orexigen, Vivus. CMA has participated on the advisory boards of Allergan, Amylin, Orexigin, Merck, Johnson & Johnson, Arena and Sanofi-Aventis, and has received research funding from Lilly, Amylin, Pfizer, Sanofi-Aventis, Orexigen, MetaProteomics and the Dr Robert C and Veronica Atkins Foundation.